CETP Inhibition in CVD Prevention: an Actual Appraisal
By virtue of their effects on low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, and cellular cholesterol efflux, there is considerable interest in the potential use of pharmacological inhibitors of cholesteryl ester transfer protein (CETP) as a novel approach for cardiovascular disease prevention. This is supported by observations from genetic and animal studies suggesting that less CETP activity has favorable cardiovascular effects. Despite the adverse effects of the first CETP inhibitor to move forward in clinical development, torcetrapib, there remains considerable interest in developing alternative CETP inhibitors without the off-target effects of torcetrapib. The clinical development programs leading to a number of promising CETP inhibitors will be reviewed.
KeywordsCETP inhibitors Lipids Cardiovascular disease Prevention Clinical trials Atherosclerosis
Compliance with Ethical Standards
Conflict of Interest
Stephen J. Nicholls reports receiving research support from AstraZeneca, Amgen, Eli Lilly, Novartis, Resverlogix, Sanofi-Regeneron, Anthera, and Cerenis and is a consultant for AstraZeneca, Amgen, Boehringer Ingelheim, CSL Behring, Eli Lilly, Merck, Takeda, Roche, Novartis, and Sanofi-Regeneron.
Kohei Takata reports grants from the Clinical Research Promotion Foundation.
Belinda Di Bartolo and MyNgan Duong declare that they have no conflict of interest.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Papers of particular interest, published recently, have been highlighted as: • Of importance
- 8.Boekholdt SM, Kuivenhoven JA, Wareham NJ, et al. Plasma levels of cholesteryl ester transfer protein and the risk of future coronary artery disease in apparently healthy men and women: the prospective EPIC (European Prospective Investigation into Cancer and nutrition)-Norfolk population study. Circulation. 2004;110:1418–23.CrossRefPubMedGoogle Scholar
- 10.Khera AV, Wolfe ML, Cannon CP, et al. On-statin cholesteryl ester transfer protein mass and risk of recurrent coronary events (from the pravastatin or atorvastatin evaluation and infection therapy—thrombolysis in myocardial infarction 22 [PROVE IT-TIMI 22] study). Am J Cardiol. 2010;106:451–6.CrossRefPubMedGoogle Scholar
- 17.•Voight BF, Peloso GM, Orho-Melander M, et al. Plasma HDL cholesterol and risk of myocardial infarction: a Mendelian randomisation study. Lancet. 2012;380:572–80. Mendelian randomization analysis suggesting that CETP plays a causative role in atherosclerotic cardiovascular disease.CrossRefPubMedPubMedCentralGoogle Scholar
- 27.Hildebrand RB, Lammers B, Meurs I, et al. Restoration of high-density lipoprotein levels by cholesteryl ester transfer protein expression in scavenger receptor class B type I (SR-BI) knockout mice does not normalize pathologies associated with SR-BI deficiency. Arterioscler Thromb Vasc Biol. 2010;30:1439–45.CrossRefPubMedGoogle Scholar
- 37.Nicholls SJ, Tuzcu EM, Brennan DM, et al. Cholesteryl ester transfer protein inhibition, high-density lipoprotein raising, and progression of coronary atherosclerosis: insights from ILLUSTRATE (Investigation of Lipid Level Management Using Coronary Ultrasound to Assess Reduction of Atherosclerosis by CETP Inhibition and HDL Elevation). Circulation. 2008;118:2506–14.CrossRefPubMedGoogle Scholar
- 41.•Barter PJ, Rye KA, Tardif JC, et al. Effect of torcetrapib on glucose, insulin, and hemoglobin A1c in subjects in the Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events (ILLUMINATE) trial. Circulation. 2011;124:555–62. Potential anti-diabetic effects of torcetrapib.CrossRefPubMedGoogle Scholar
- 47.Tardif JC, Rheaume E, Lemieux Perreault LP. Pharmacogenomic determinants of the cardiovascular effects of dalcetrapib. circulation. Cardiovasc Genet. 2015.Google Scholar
- 49.Gotto Jr AM, Cannon CP, Li XS, et al. Evaluation of lipids, drug concentration, and safety parameters following cessation of treatment with the cholesteryl ester transfer protein inhibitor anacetrapib in patients with or at high risk for coronary heart disease. Am J Cardiol. 2014;113:76–83.CrossRefPubMedGoogle Scholar